Literature DB >> 3571974

Identification of a deletion in the adenosine deaminase gene in a child with severe combined immunodeficiency.

M L Markert, M S Hershfield, D A Wiginton, J C States, F E Ward, S H Bigner, R H Buckley, R E Kaufman, J J Hutton.   

Abstract

A patient with adenosine deaminase-deficient severe combined immunodeficiency is described whose defect is secondary to deletion of a portion of the ADA structural gene. In Southern analyses, DNA from this patient does not hybridize to a genomic probe that includes the 3' end of exon 1. This implies that both his parents are heterozygous for deletions of exon 1 sequences. Consistent with this finding, the patient has no detectable adenosine deaminase mRNA by Northern analysis. This is the first report of a deletion mutation as the cause of adenosine deaminase deficiency.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571974

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements.

Authors:  M L Markert; J J Hutton; D A Wiginton; J C States; R E Kaufman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 2.  The map of chromosome 20.

Authors:  N E Simpson
Journal:  J Med Genet       Date:  1988-12       Impact factor: 6.318

3.  Expression of human adenosine deaminase in murine hematopoietic cells.

Authors:  J W Belmont; G R MacGregor; K Wager-Smith; F A Fletcher; K A Moore; D Hawkins; D Villalon; S M Chang; C T Caskey
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

4.  Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency.

Authors:  R Hirschhorn; S Tzall; A Ellenbogen; S H Orkin
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).

Authors:  R Hirschhorn; V Chakravarti; J Puck; S D Douglas
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

Review 6.  Displacement bone marrow transplantation for some inborn errors.

Authors:  J R Hobbs
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

7.  Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.

Authors:  F X Arredondo-Vega; I Santisteban; S Kelly; C M Schlossman; D T Umetsu; M S Hershfield
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

8.  Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency.

Authors:  M R Aust; L G Andrews; M J Barrett; C J Norby-Slycord; M L Markert
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

9.  Adenosine deaminase gene expression is regulated posttranscriptionally in the nucleus.

Authors:  T M Berkvens; F Schoute; H van Ormondt; P Meera Khan; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

10.  A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution.

Authors:  M L Markert; C Norby-Slycord; F E Ward
Journal:  Am J Hum Genet       Date:  1989-09       Impact factor: 11.025

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.